Prellis Biologics · 3 months ago
Principal Scientist - Antibody Discovery
Berkeley, CA
Full-time
Hybrid
Senior Level, Lead/Staff
$150K/yr - $195K/yr
3+ years expPrellis Biologics is a pre-IPO biotech company focused on revolutionizing drug discovery through the integration of human biology and machine learning. They are seeking a highly motivated and experienced Principal Scientist in Antibody Discovery to lead innovative research initiatives and support various discovery studies while managing lab staff and external partnerships.
3D PrintingBiopharmaBiotechnologyTherapeutics
Responsibilities
Antibody discovery: Will lead a team of scientists on Prellis’ breakthrough EXIS (lymph node organoid) platform, novel 10X and Single B-cell cloning methods, combined with NGS to discover antibodies for a range of portfolio therapeutic targets
Molecular biology: Will contribute to innovation in molecular biology of antibody cloning, expression, and generation of NGS libraries
Data analysis: Will utilize advanced bioinformatics tools and techniques to analyze large NGS datasets, including V-genes, and B-cell transcriptomic for antibody discovery and development. The ability to use antibody sequence data and associated properties to train predictive and generative ML-models will be considered as a plus
Mentorship: Provide guidance to Ph.D. and non-Ph.D. scientists in immunology, data science, and molecular biology
Collaboration: The ability to multi-task and manage multiple projects, whilst working closely with data scientists, immunologists, protein engineers, and molecular biologists to translate bioinformatics findings into actionable insights for therapeutic development. Lead cross-functional teams to achieve project goals
Communication: Strong verbal and written communication skills with a high degree of motivation, creativity and collaborative qualities.Present research findings clearly and effectively to internal stakeholders. Prepare detailed reports and presentations
Qualification
Required
Ph.D. in molecular biology, immunology, bioinformatics, or a related field
Ph.D. in Biochemistry, Molecular Biology, Cell Biology, Immunology, or a related field with 3-4 years of relevant experience within an academic or industrial setting; or Master's degree and 5 years of relevant experience within an academic or industrial setting; or Bachelor's degree and 7 years of relevant experience within an academic or industrial setting
Proficiency in antibody discovery techniques, B-cell biology, and therapeutic development processes
Experience with bioinformatics tools for antibody sequence analysis, structural modeling, and machine learning applications
Strong problem-solving abilities
Excellent communication skills
Capacity to work effectively in a multidisciplinary team
Preferred
The ability to use antibody sequence data and associated properties to train predictive and generative ML-models will be considered as a plus
Knowledge in programming languages such as Python or R for data analysis will be a plus
Benefits
A competitive employee benefits package, including group medical, dental and vision coverage, life and disability insurance, flexible spending accounts an a 401(k) plan
Stock-based long term incentives
Holiday package including a 1+ week winter shutdown
Flexible work models, including remote and hybrid working arrangements, where possible
Company
Prellis Biologics
Prellis employs holographic tissue printing technology with fully human antibody discovery, in vitro human disease and ADME/Tox models.
11-50 employees
H1B Sponsorship
Prellis Biologics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (1)
2023 (2)
Funding
Current Stage
Growth StageTotal Funding
$79.37MKey Investors
Celesta CapitalKhosla VenturesTrue Ventures
2025-03-10Series C
2023-11-17Series C
2022-08-10Series C· $35M
Leadership Team
Michael Nohaile
Chief Executive Officer
Recent News
Corridor Business Journal
2025-11-26
Company data provided by crunchbase